Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SPTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Seaport Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Seaport Therapeutics, Inc.
Upcoming catalysts 2
Event history 24
Past FDA Catalysts and PDUFA Decisions
How SPTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-11 | GlyphAgo (SPT-320, Glyph Agomelatine) | Phase 1 data presentation | Phase 1 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SPT-300 Small MoleculesNCT07161700 | Major Depressive Disorder (MDD) | Phase 2 | ENROLLING BY_INVITATION | 720 | May 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every SPTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| GlyphAllo | driving performance | Phase 1 | 2026-11-02 | GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5; a single evening dose of 250 mg GlyphAllo did not impair next-morning driving performance compared to placebo on Day 2Read More | Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Torres DeniceDirector | Buy | 5,000 5,000 held | $19.87 | 11/03/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SPTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 3.1 % (-22.5 %) | 71.90 M | 3.56 M |
Ownership Trends
SPTX Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How SPTX ranks across every disease it competes in
SPTX News
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics reported positive topline data from its Phase 1 trial of GlyphAllo, indicating no impairment in driving performance. The company has initiated a Phase 2a trial for GlyphAgo in generalized anxiety disorder and is on track with enrollment for its Phase 2b BUOY-1 trial for major depressive disorder. Seaport's financial position remains strong, with $403.8 million in cash.
Read more →Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference
Seaport Therapeutics will present at the Stifel 2026 Healthcare Conference from November 10-12, 2026. The management team is scheduled to speak on November 10 at 4:00 p.m. EST. The company will also hold one-on-one meetings with investors during the event. A live webcast will be available on their website.
Read more →Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Seaport Therapeutics has presented additional pharmacokinetic data from its Phase 1 clinical trial of GlyphAgo™ at the 39th ECNP Congress in Munich. This marks the first scientific presentation of data related to GlyphAgo™, a novel neuropsychiatric medicine. The event highlights Seaport's commitment to advancing its therapeutic pipeline.
Read more →PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Seaport Therapeutics, a company founded by PureTech, has announced the dosing of the first patient in its Phase 2a clinical trial for GlyphAgo™. This trial aims to evaluate the efficacy of GlyphAgo™ in patients suffering from generalized anxiety disorder and sleep disturbances. The development marks a significant step forward in addressing these mental health challenges.
Read more →Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Seaport Therapeutics has announced that the first patient has been dosed in its Phase 2a clinical trial for GlyphAgo. This trial aims to evaluate the efficacy of GlyphAgo in treating patients with generalized anxiety disorder and sleep disturbances. The development represents a significant step forward in addressing these mental health conditions.
Read more →Seaport Therapeutics to Participate in September Investor Conferences
Seaport Therapeutics, a clinical-stage company focused on neuropsychiatric medicines, announced its participation in several investor conferences in September. The events will include a presentation and panel discussion led by CEO Daphne Zohar at the Goldman Sachs Life Sciences Symposium. This engagement aims to enhance investor relations and showcase the company's developments.
Read more →Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
Seaport Therapeutics has announced positive topline results from its Phase 1 driving simulation trial of GlyphAllo™. The trial, conducted with healthy volunteers, indicates the potential safety and efficacy of the product. This development marks a significant step forward for Seaport Therapeutics in their research efforts.
Read more →Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
Seaport Therapeutics has announced its participation in two significant events: Citi's 2026 Biopharma Back to School Conference and the 21st Annual Wells Fargo Healthcare Conference. These presentations are expected to provide insights into the company's developments and foster investor relations. The participation reflects the company's commitment to engaging with the biopharma community.
Read more →Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics has announced its financial results for the second quarter of 2026, showcasing notable corporate and clinical advancements. The report emphasizes the company's ongoing progress in its initiatives, reflecting a positive outlook for future developments.
Read more →PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics, a company founded by PureTech, has announced positive results from its Phase 1 proof-of-concept trial of GlyphAgo™. The trial involved healthy volunteers and demonstrated encouraging data regarding the drug's safety and efficacy. These findings suggest potential for further development in the therapeutic landscape.
Read more →Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics reported its Q1 2026 financial results, highlighting advancements in its clinical programs for neuropsychiatric disorders. The company is actively enrolling patients in the Phase 2b BUOY-1 trial for GlyphAllo, with topline data expected in early 2027. Additionally, new data from the GlyphAgo program indicate promising safety and efficacy profiles. The recent IPO raised $260 million to support ongoing development.
Read more →Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics has announced positive results from a Phase 1 proof-of-concept trial for GlyphAgo™, demonstrating its safety and tolerability in healthy volunteers. The multiple-ascending dose data supports further development of the therapy. This marks a significant milestone for the company in advancing GlyphAgo™.
Read more →Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
Seaport Therapeutics, a clinical-stage company, announced its participation in two upcoming investor conferences: the Goldman Sachs 47th Annual Global Healthcare Conference and the UBS Virtual CNS Day. Management will engage in fireside chats and one-on-one meetings, showcasing their commitment to investor relations. The company focuses on developing novel treatments for neuropsychiatric disorders.
Read more →Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering
Seaport Therapeutics has announced the pricing of its upsized initial public offering, offering 14,160,000 shares at $18.00 each, totaling approximately $254.9 million. The shares are set to begin trading on the Nasdaq Global Select Market on May 1, 2026. The offering is expected to close on May 4, 2026, pending customary conditions.
Read more →Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
Seaport Therapeutics has appointed Dr. Sharon Mates, the founder and former CEO of Intra-Cellular Therapies, to its Board of Directors. Dr. Mates has a strong background in neuropsychiatry and played a key role in the commercialization of the antipsychotic CAPLYTA. Her expertise is expected to enhance Seaport's mission to develop innovative treatments for neuropsychiatric disorders.
Read more →Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics announced positive topline results from its Phase 1 trial of GlyphAgo, a novel prodrug of agomelatine. The trial demonstrated a significant increase in bioavailability and reduced pharmacokinetic variability. GlyphAgo was well-tolerated, with no serious adverse effects reported, paving the way for further clinical trials in generalized anxiety disorder.
Read more →Seaport Therapeutics Announces Science Translational Medicine Peer-Reviewed Publication Featuring GlyphAllo (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
Seaport Therapeutics announced the publication of findings on GlyphAllo, a novel oral prodrug of allopregnanolone, in Science Translational Medicine. The study confirms its therapeutic potential in major depressive disorder (MDD) and supports the ongoing Phase 2b trial. GlyphAllo's unique formulation allows for enhanced bioavailability, making it a promising candidate for treating MDD.
Read more →Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function
Seaport Therapeutics has received up to $15 million from ARPA-H to advance GlyphCele, an oral prodrug targeting gut lymphatic dysfunction. This innovative therapy aims to address issues linked to metabolic diseases and pancreatic cancer by restoring lymphatic function. The collaboration with Monash Institute of Pharmaceutical Sciences enhances the potential impact of this research.
Read more →Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials
Seaport Therapeutics presented a meta-analysis at the ISCTM Conference, revealing that clinician-administered assessments significantly influence placebo responses in generalized anxiety disorder trials. The study examined 22 trials and found no strong correlation with other design factors. This research builds on previous findings in major depressive disorder, emphasizing the need for optimized clinical trial designs to enhance drug development success.
Read more →Seaport Therapeutics to Participate in Upcoming Investor Conferences in February and March
Seaport Therapeutics has announced its participation in several upcoming investor conferences in February and March 2026. The conferences include the Oppenheimer 36th Annual Healthcare Life Sciences Conference, the Leerink Partners Global Healthcare Conference, and the Stifel 2026 Virtual CNS Forum. The company aims to showcase its advancements in neuropsychiatric medicines and highlight its proprietary Glyph technology platform.
Read more →